A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Multiple Myeloma
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Subjects with measurable multiple myeloma who have progressed on, or could not tolerate, all available established therapies. 2) Subject must have documented evidence of progressive disease based on investigator’s determination of response by the International Myeloma Working Group (IMWG) 2016 criteria on or within 12 months of their last line of therapy.

You may not be eligible for this study if the following are true:

  • 1) Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2) Known to be seropositive for human immunodeficiency virus or acquired immune deficiency syndrome. 3) Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.